These findings suggest modulating microglial activity by enhancing Aβ clearance (e.g., via TREM2 agonism) or suppressing maladaptive inflammation (e.g., through NOD-like receptor thermal protein domain associated protein 3—NLRP3 inflammasome inhibition) could mitigate AD progression. This evidence concerns the gene NLRP3 and Alzheimer disease.